[go: up one dir, main page]

CO6960546A2 - Immediate release formulation of 4-methyl-3 [[4- (3-pyridinyl) -2pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro- methyl) -phenyl] -benzamide - Google Patents

Immediate release formulation of 4-methyl-3 [[4- (3-pyridinyl) -2pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro- methyl) -phenyl] -benzamide

Info

Publication number
CO6960546A2
CO6960546A2 CO14103891A CO14103891A CO6960546A2 CO 6960546 A2 CO6960546 A2 CO 6960546A2 CO 14103891 A CO14103891 A CO 14103891A CO 14103891 A CO14103891 A CO 14103891A CO 6960546 A2 CO6960546 A2 CO 6960546A2
Authority
CO
Colombia
Prior art keywords
methyl
benzamide
imidazol
pyridinyl
trifluoro
Prior art date
Application number
CO14103891A
Other languages
Spanish (es)
Inventor
Upkar Bhardwaj
Magesh Sadashiv Bordawekar
Anne Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6960546A2 publication Critical patent/CO6960546A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO14103891A 2011-11-14 2014-05-14 Immediate release formulation of 4-methyl-3 [[4- (3-pyridinyl) -2pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro- methyl) -phenyl] -benzamide CO6960546A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
CO6960546A2 true CO6960546A2 (en) 2014-05-30

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14103891A CO6960546A2 (en) 2011-11-14 2014-05-14 Immediate release formulation of 4-methyl-3 [[4- (3-pyridinyl) -2pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro- methyl) -phenyl] -benzamide

Country Status (22)

Country Link
EP (1) EP2779995A1 (en)
JP (1) JP6275645B2 (en)
KR (1) KR20140093230A (en)
CN (1) CN103930094A (en)
AR (1) AR088844A1 (en)
BR (1) BR112014011518A2 (en)
CA (1) CA2855503A1 (en)
CL (1) CL2014001247A1 (en)
CO (1) CO6960546A2 (en)
EA (1) EA201490960A1 (en)
GT (1) GT201400094A (en)
HK (1) HK1197025A1 (en)
IL (1) IL232480A0 (en)
IN (1) IN2014DN03416A (en)
MA (1) MA35636B1 (en)
MX (1) MX2014005874A (en)
PE (1) PE20141337A1 (en)
SG (2) SG11201401476TA (en)
TN (1) TN2014000177A1 (en)
TW (1) TWI574690B (en)
WO (1) WO2013074432A1 (en)
ZA (1) ZA201402756B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (en) 2017-12-20 2019-07-03 Zentiva, K.S. Dosing of crystalline nilotinib
JP7378279B2 (en) * 2019-11-18 2023-11-13 日本化薬株式会社 Pharmaceutical tablet containing nilotinib as an active ingredient and method for producing the same
JP7489849B2 (en) 2020-07-20 2024-05-24 日本化薬株式会社 Nilotinib tablets

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (en) 2005-07-20 2007-03-19 CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA
GT200600316A (en) 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
IN2011CH01887A (en) * 2011-06-02 2012-12-14

Also Published As

Publication number Publication date
SG11201401476TA (en) 2014-10-30
HK1197025A1 (en) 2015-01-02
ZA201402756B (en) 2015-04-29
CA2855503A1 (en) 2013-05-23
CL2014001247A1 (en) 2014-10-17
JP2014533283A (en) 2014-12-11
NZ623844A (en) 2016-09-30
TWI574690B (en) 2017-03-21
AU2012339829B2 (en) 2016-05-12
JP6275645B2 (en) 2018-02-07
MX2014005874A (en) 2014-06-23
TN2014000177A1 (en) 2015-09-30
PE20141337A1 (en) 2014-10-16
EA201490960A1 (en) 2014-08-29
GT201400094A (en) 2017-09-28
IL232480A0 (en) 2014-06-30
EP2779995A1 (en) 2014-09-24
IN2014DN03416A (en) 2015-06-26
SG10201707768RA (en) 2017-10-30
KR20140093230A (en) 2014-07-25
BR112014011518A2 (en) 2017-05-16
WO2013074432A1 (en) 2013-05-23
TW201325594A (en) 2013-07-01
AR088844A1 (en) 2014-07-10
AU2012339829A1 (en) 2014-05-29
MA35636B1 (en) 2014-11-01
CN103930094A (en) 2014-07-16

Similar Documents

Publication Publication Date Title
CO6801777A2 (en) Modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro -methyl) -phenyl] -benzamide solubilized using organic acids
FR23C1050I2 (en) COMPOUND OF 3,5-DISUBSTITUTED ALKYNYLBENZENE AND A SALT THEREOF
CY2020017I2 (en) SUBSTITUTED 4-PHENYL-PYRIDINES FOR THE TREATMENT OF NK-1 RECEPTOR RELATED DISEASES
HK1217487A1 (en) N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addiction -2 n-[4-(2--12---4- )-]-
IL239025B (en) Fxr agonist for treatment of pulmonary disease
CO6811863A2 (en) Compounds of 2- (2,4,5-substituted anilino) pyrimidine
HUE028396T2 (en) Condensed heterocyclic compounds and their use for pest control
HK1220978A1 (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-ymesylate monohydrate n-[5-()-4--13--2-]-n--2-[4-(2-)]
PL2421832T3 (en) N-alkoxyamides of 6-(substituted phenyl)-4-aminopicolinates and 2-(substituted phenyl)-6-amino-4-pyrimidinecarboxylates and their use as selective herbicides for crops
DK3409278T3 (en) Heterocyclic protein kinase inhibitors
BR112012017375A2 (en) disposable article of clothing
EP2758389A4 (en) CARBOXAMIDES OF PYRAZOLE AS INHIBITORS OF JANUS KINASE
LT2782570T (en) HETEROCYCLIC INHIBITORS OF GLUTAMINASE
HUE037154T2 (en) Substituted benzylindazole derivatives as Bub1 kinase inhibitors for the treatment of hyperproliferative diseases
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
DK2878598T3 (en) Crystalline Form of 4- [5- (PYRIDIN-4-YL) -1H-1,2,4-TRIAZOL-3-YL] PYRIDIN-2-CARBONITRIL
LT3160958T (en) CRYSTALLINE SALTS OF (S) -6 - ((1-ACETYLPIPERIDIN-4-IL) AMINO) -N- (3- (3,4-DIHYDROIZOCHINOLIN-2 (1H) -YL) -2-HYDROXYPROPYL) PYRIMIDINE-4-CARBOXAMIDE
SMT201600304B (en) SALT CHLORIDRATE OF 4- [2 - [[5-METHYL-1- (2- NAFTALENYL] -1H-PIRAZOL-3- IL] OXY] ETYL] MORPHOLIN
HUE041725T2 (en) CRYSTAL OF (S)-1-(2-HYDROXYETHYL)-4-METHYL-N- [4-(METHYLSULFONYL)PHENYL]-5-[2-(TRIFLUOROMETHYL)& xA;PHENYL]- 1H-PYRROLE-3-CARBOXAMIDE
IL234742A0 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
EP2699569A4 (en) AMINOPYRIMIDINE KINASE INHIBITORS
PL2658851T3 (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
WO2013150545A3 (en) Process for preparation of benzimidazole derivatives and salts thereof
CO6960546A2 (en) Immediate release formulation of 4-methyl-3 [[4- (3-pyridinyl) -2pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro- methyl) -phenyl] -benzamide
EP2694465A4 (en) ORTHO-FLUORO COMPOUNDS SUBSTITUTED FOR TREATING METABOLIC DISEASES